VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

“…VRK1 score was determined by multiplying the VRK1 staining intensity × percentage of VRK1 positive staining. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0203397#pone.0203397.g008" target="_blank">Fig 8A</a> includes the data from all primary tumor and lymph node samples. …”

Decreased proliferation in <i>AnxA2</i>kd and <i>AnxA5</i>kd cells. by Damian C. Genetos (325684)

EQI decreases malonyl-CoA levels in <i>S</i>. <i>aureus</i>. by Erica C. Larson (1344687)

A647D decreased mexiletine sensitivity of P1332L when coexpressed. by Jie Liu (15128)

Progressive decrease in expression of Kcnj10, Kcnq1, Gjb2 and Gjb6 in <i>Spns2^tm1a/tm1a</i> mice. by Jing Chen (4762)

A: Top, representative recording of the application, for 10 seconds, of different concentrations of tribendimidine which produces a depolarization (upward movement of the thickest line) and increase in membrane conductance (decrease in the width of the trace). by Alan P. Robertson (362793)

PIMT decreased the formation of amyloid-like fibrils of H79A alanine substituent of αA66–80 peptides. by Kosuke Magami (10654473)

Decreasing phosphorylation of Moesin, MLC, and Cofilin in border cells without <i>twins</i> function. by Po-An Yeh (210960)

DNMT1 knock down decreases HDAC1 binding to RGS10 promoters in chemoresistant ovarian cancer cells. by Ercan Cacan (393523)

SARS-CoV-2 induced lung inflammation is increased with IL-10 blockade and decreased with IFNγ blockade. by Christine E. Nelson (18946410)

Glucose inhibition decreases IL-1β levels and tumor progression in the B16F10 mouse model. by Yunseo Woo (6157307)

Systemic inhibition of CSF-1R decreases B16F10-induced accumulation of blood monocyte subsets. by Marjolein Sluijter (613087)

Image 10_Decreased neuronal and increased endothelial fractalkine expression are associated with neuroinflammation in Parkinson’s disease and related disorders.tif by Yaping Chu (789771)

A targeted RNAi screen identifies 17 RNAi candidates that decrease the prolonged lifespan of the METC mutant <i>isp-1;ctb-1</i> by at least 10%. by Ludivine Walter (216669)

“…Among them, 13 represent transcription factors not previously known to function in aging and four (indicated with asterisks) are transcription factors already known to affect lifespan in <i>C. elegans</i>: HSF-1 <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001084#pbio.1001084-Hsu1" target="_blank">[31]</a>, NHR-49 <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001084#pbio.1001084-VanGilst1" target="_blank">[32]</a>, DAF-16 <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001084#pbio.1001084-Kenyon1" target="_blank">[33]</a>, and PHA-4 <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001084#pbio.1001084-Panowski1" target="_blank">[34]</a>. …”

RvD1 decreases production of pro-inflammatory mediators in BALF and total lung homogenate but increases IL-10. by Hsi-Min Hsiao (385810)

Metformin lotion decreases TGF-β1 levels in the wounded skin of rats after 10 days of wound healing. by Jianying Zhang (256508)

<i>sox10</i> mutants have decreased intestinal transit and hyperpermeability, independent of intestinal microbially induced inflammation. by M. Kristina Hamilton (9162785)

The change in value of the Kruskal-Wallis H Test for the first 10 components of the Blood PCA as the platform-variance threshold is decreased. by Paul W. Angel (9427740)

Mast cell density and tactile sensitivity decreased after 10 preventative imatinib treatments followed by repeated MI challenges. by Jaclyn M. Kline (9565161)

“…<p>For preventative imatinib treatment, mice were treated with 100 μL of 30 mg/kg imatinib dissolved in 0.9% saline injected intraperitoneally 30 minutes before each of 10 daily MI challenges. (A) Density of avidin⁺ mast cells in 10 μm labiar skin cryo-sections from sensitized mice receiving NT or preventatively treated with imatinib and challenged 10 times daily with MI. …”

AAMs compared to CAMs show decreased CCL13 expression and increased IL-10 production post BCG infection. by Soumya Chatterjee (473957)